Real-world baseline treatment patterns and overall survival (rwOS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in the United States.

被引：0
|
作者：
Kariburyo-Yay, Furaha
George, Daniel J.
Aggarwal, Himani
Tepsick, Jon G.
Yu, Rebekah
Li, Weiyan
Orji, Chinelo
Lal, Lincy S.
Ghate, Sameer R.
机构：
[1] ConcertAI LLC, Cambridge, MA USA
[2] Duke Univ, Inst Canc, Durham, NC USA
[3] Merck & Co Inc, Rahway, NJ USA
[4] AstraZeneca, Gaithersburg, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5054
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The prostate cancer registry.
    Chowdhury, Simon
    Birtle, Alison J.
    Bjartell, Anders
    Costa, Luis
    Feyerabend, Susan
    Galli, Luca
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [42] Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients.
    Higano, Celestia S.
    Sternberg, Cora N.
    Saad, Fred
    Tombal, Bertrand F.
    Miller, Kurt
    Kalinovsky, Jan
    Jiao, XiaoLong
    Tangirala, Krishna
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [43] REAL-WORLD DATA ANALYSIS OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) TREATMENT DECISIONS WITH THE INTRODUCTION OF NEWER TREATMENT OPTIONS
    Scott, J.
    Concepcion, R.
    Garofalo, D.
    Verma-Kurvari, S.
    Xu, B.
    Montgomery, J.
    VALUE IN HEALTH, 2018, 21 : S43 - S43
  • [44] Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe
    Castro, Elena
    Orji, Chinelo
    Ribbands, Amanda
    Butcher, Jake
    Walley, Maria
    Li, Weiyan
    Ghate, Sameer R.
    FUTURE ONCOLOGY, 2025,
  • [45] Predictors of overall survival in patients with metastatic castration-resistant prostate cancer
    Markova, A. S.
    Polikarpova, S. B.
    Kamolov, B. Sh.
    Gridneva, Ya. V.
    Kalinin, S. A.
    Peters, M. V.
    Matveev, V. B.
    ONKOUROLOGIYA, 2015, 11 (02): : 77 - 84
  • [46] Exploratory gene-by-gene analysis of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROfound.
    De Bono, Johann S.
    Matsubara, Nobuaki
    Penel, Nicolas
    Mehra, Niven
    Kolinsky, Michael Paul
    Bompas, Emmanuelle
    Feyerabend, Susan
    Gravis, Gwenaelle
    Joung, Jae Young
    Nishimura, Kazuo
    Gedye, Craig
    Mateo, Joaquin
    Saad, Fred
    Fizazi, Karim
    Shore, Neal
    Kang Jinyu
    Desai, Chintu
    Burgents, Joseph E.
    Harrington, Elizabeth
    Hussain, Maha H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [47] REAL-WORLD TREATMENT PATTERNS AND TREATMENT SEQUENCES IN THE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER SETTINGS ACROSS EUROPE
    Castro, E.
    Orji, C.
    Ribbands, A.
    Butcher, J.
    Walley, M.
    Li, W.
    Ghate, S.
    VALUE IN HEALTH, 2024, 27 (06) : S227 - S227
  • [48] Statin use and outcome in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated in the TROPIC trial
    Lorente, D.
    De Velasco Oria, G. A.
    Carles, J.
    Gillessen, S.
    Fizazi, K.
    Joshua, A.
    Eisenberger, M.
    Sartor, O.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [49] Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.
    Clarke, Noel
    Wiechno, Pawel J.
    Alekseev, Boris
    Sala, Nuria
    Jones, Robert
    Kocak, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] Response to olaparib or carboplatin in a real-world cohort of men with DNA damage repair (DDR) deficient metastatic castration-resistant prostate cancer (mCRPC)
    Berchuck, Jacob E.
    Silver, Rebecca
    Bakouny, Ziad
    Abou Alaiwi, Sarah
    Hamid, Anis
    Sweeney, Christopher
    Freedman, Matthew L.
    Pomerantz, Mark
    Taplin, Mary-Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345